JP2016531153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531153A5 JP2016531153A5 JP2016542369A JP2016542369A JP2016531153A5 JP 2016531153 A5 JP2016531153 A5 JP 2016531153A5 JP 2016542369 A JP2016542369 A JP 2016542369A JP 2016542369 A JP2016542369 A JP 2016542369A JP 2016531153 A5 JP2016531153 A5 JP 2016531153A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- nhr
- nhc
- cancer
- saturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 33
- 229920006395 saturated elastomer Polymers 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 125000006413 ring segment Chemical group 0.000 claims 21
- -1 pyrrolidino, piperidino, piperazino, morpholino Chemical group 0.000 claims 20
- 125000005842 heteroatom Chemical group 0.000 claims 19
- 229910052757 nitrogen Inorganic materials 0.000 claims 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 12
- 125000002947 alkylene group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims 6
- 230000003902 lesion Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010049422 Precancerous skin lesion Diseases 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 206010058314 Dysplasia Diseases 0.000 claims 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 4
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 claims 4
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 241000700584 Simplexvirus Species 0.000 claims 4
- 208000009973 brain hypoxia - ischemia Diseases 0.000 claims 4
- 230000007812 deficiency Effects 0.000 claims 4
- 201000006902 exudative vitreoretinopathy Diseases 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 208000033300 perinatal asphyxia Diseases 0.000 claims 4
- 201000005936 periventricular leukomalacia Diseases 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 3
- 230000005856 abnormality Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 201000001937 osteoporosis-pseudoglioma syndrome Diseases 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 208000007122 AIDS-Associated Nephropathy Diseases 0.000 claims 2
- 208000022099 Alzheimer disease 2 Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010012305 Demyelination Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010061159 Foot deformity Diseases 0.000 claims 2
- 208000013875 Heart injury Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000005410 Mediastinal Neoplasms Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 208000004286 Osteochondrodysplasias Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 2
- 208000022617 SERKAL syndrome Diseases 0.000 claims 2
- 201000010096 SOST-related sclerosing bone dysplasia Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010072610 Skeletal dysplasia Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 2
- 206010047486 Virilism Diseases 0.000 claims 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 230000037182 bone density Effects 0.000 claims 2
- 206010006007 bone sarcoma Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000004190 glucose uptake Effects 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 230000007574 infarction Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 231100000794 masculinization Toxicity 0.000 claims 2
- 201000000349 mediastinal cancer Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 201000011682 nervous system cancer Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 230000032724 odontogenesis Effects 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 201000002314 small intestine cancer Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000022345 tetraamelia syndrome Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 101000663006 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-1 Proteins 0.000 claims 1
- 101000662592 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 claims 1
- 102100037664 Poly [ADP-ribose] polymerase tankyrase-1 Human genes 0.000 claims 1
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 claims 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 210000000276 neural tube Anatomy 0.000 claims 1
- 230000001009 osteoporotic effect Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1316173.2 | 2013-09-11 | ||
| GBGB1316173.2A GB201316173D0 (en) | 2013-09-11 | 2013-09-11 | Compounds and their therapeutic use |
| GBGB1403496.1A GB201403496D0 (en) | 2014-02-27 | 2014-02-27 | Compounds and their therapeutic use |
| GB1403496.1 | 2014-02-27 | ||
| GB1410387.3 | 2014-06-11 | ||
| GB201410387A GB201410387D0 (en) | 2014-06-11 | 2014-06-11 | Compounds and their therapeutic use |
| PCT/GB2014/052752 WO2015036759A1 (en) | 2013-09-11 | 2014-09-11 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016531153A JP2016531153A (ja) | 2016-10-06 |
| JP2016531153A5 true JP2016531153A5 (cg-RX-API-DMAC7.html) | 2017-10-12 |
| JP6456392B2 JP6456392B2 (ja) | 2019-01-23 |
Family
ID=51564774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542369A Expired - Fee Related JP6456392B2 (ja) | 2013-09-11 | 2014-09-11 | ３−アリール−５−置換イソキノリン−１−オン化合物及びその治療的使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9611223B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3044221B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6456392B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105722835B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014320149A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2922469A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3044221T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2666729T3 (cg-RX-API-DMAC7.html) |
| NO (1) | NO3044221T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015036759A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018008630A2 (pt) | 2015-11-06 | 2018-10-30 | Neurocrine Biosciences Inc | derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida, seus usos, composição farmacêutica |
| EA039638B1 (ru) * | 2016-01-06 | 2022-02-21 | Нейрокрин Байосайенсиз, Инк. | Антагонисты мускаринового рецептора 4 и способы их применения |
| CN107286169B (zh) * | 2016-04-05 | 2020-11-24 | 北京四环制药有限公司 | 端锚聚合酶抑制剂 |
| GB201615282D0 (en) * | 2016-09-08 | 2016-10-26 | Univ Bath | Tankyrase inhibitors |
| EP3459469A1 (en) | 2017-09-23 | 2019-03-27 | Universität Zürich | Medical occluder device |
| US12402885B2 (en) | 2017-09-23 | 2025-09-02 | Universität Zürich | Medical occlusion device |
| CN110003049A (zh) * | 2019-05-13 | 2019-07-12 | 苏州山青竹生物医药有限公司 | 一种制备4-氰基-1-茚酮的方法 |
| CN110407740A (zh) * | 2019-09-04 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种3-溴-2-乙基吡啶的合成方法 |
| CN114641242B (zh) | 2019-09-26 | 2025-11-18 | 苏黎世大学 | 左心耳闭塞装置 |
| ES2983860T3 (es) | 2019-12-06 | 2024-10-25 | Neurocrine Biosciences Inc | Antagonistas del receptor muscarínico 4 y métodos de uso |
| WO2022235492A1 (en) * | 2021-05-04 | 2022-11-10 | Board Of Regents, The University Of Texas System | Indanone and tetralone-keto or hydroxyl oximes as cancer therapeutics |
| EP4444305A2 (en) * | 2022-02-16 | 2024-10-16 | Duke Street Bio Limited | Pharmaceutical compound |
| GB2634228A (en) * | 2023-10-02 | 2025-04-09 | Duke Street Bio Ltd | PARP1 inhibitor compounds |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2851458A (en) | 1955-06-08 | 1958-09-09 | Burroughs Wellcome Co | Diquaternary compounds and the manufacture thereof |
| US4678500A (en) | 1984-06-29 | 1987-07-07 | E. I. Du Pont De Nemours And Company | Herbicidal 2,6-disubstituted benzylsulfonamides and benzenesulfamates |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US4942163A (en) | 1989-03-07 | 1990-07-17 | E. I. Du Pont De Nemours And Company | 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents |
| WO1999018077A1 (en) | 1997-10-02 | 1999-04-15 | Eisai Co., Ltd. | Fused pyridine derivatives |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| EP1396488A1 (en) | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| RS51444B (sr) | 2001-09-21 | 2011-04-30 | Bristol-Myers Squibb Company | JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| MXPA05000983A (es) | 2002-07-24 | 2005-08-18 | Kyorin Seiyaku Kk | Derivados de 4-(aril substituido)-5-hidroxiisoquinolinona. |
| DK1557414T3 (da) | 2002-10-01 | 2012-05-29 | Mitsubishi Tanabe Pharma Corp | IsoquinoIin-forbindelser og medicinsk anvendelse deraf |
| JP2006506379A (ja) | 2002-10-23 | 2006-02-23 | グレンマーク・ファーマシューティカルズ・リミテッド | 炎症性およびアレルギー性疾患の治療に有用な新規三環式化合物：その調製方法およびそれらを含む医薬組成物 |
| ATE540928T1 (de) * | 2002-11-22 | 2012-01-15 | Mitsubishi Tanabe Pharma Corp | Isochinolinverbindungen und ihre medizinische verwendung |
| ATE496893T1 (de) | 2002-12-20 | 2011-02-15 | X Ceptor Therapeutics Inc | Isochinolinonderivate und deren verwendung als medikamente |
| US7173004B2 (en) | 2003-04-16 | 2007-02-06 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus |
| TW200536830A (en) * | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| WO2005075432A1 (ja) | 2004-02-06 | 2005-08-18 | Chugai Seiyaku Kabushiki Kaisha | １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用 |
| WO2005113540A1 (ja) | 2004-05-20 | 2005-12-01 | Mitsubishi Pharma Corporation | イソキノリン化合物及びその医薬用途 |
| WO2006045010A2 (en) | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| JP5046950B2 (ja) | 2004-10-22 | 2012-10-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｃ−ｆｍｓキナーゼのインヒビター |
| MX2007007027A (es) | 2004-12-16 | 2007-07-04 | Hoffmann La Roche | Derivados piperazinilpiridina como agentes anti-obesidad. |
| TWI389897B (zh) | 2005-02-22 | 2013-03-21 | Chugai Pharmaceutical Co Ltd | 1- (2H) -isoquinolinone derivatives |
| BRPI0609625A2 (pt) | 2005-03-31 | 2010-04-20 | Astellas Pharma Inc | derivados de propano-1,3-diona ou sal destes |
| WO2007016525A2 (en) | 2005-07-29 | 2007-02-08 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| US7652028B2 (en) | 2005-08-24 | 2010-01-26 | Inotek Pharmaceuticals Corporation | Indenoisoquinolinone analogs and methods of use thereof |
| EP2035380A2 (en) * | 2006-06-15 | 2009-03-18 | Kudos Pharmaceuticals Limited | Parp inhibitors |
| CN101511796B (zh) | 2006-09-05 | 2012-05-09 | 协和发酵麒麟株式会社 | 咪唑衍生物 |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008092231A1 (en) | 2007-02-01 | 2008-08-07 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| FR2919286A1 (fr) | 2007-07-27 | 2009-01-30 | Sanofi Aventis Sa | Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique. |
| US20090054392A1 (en) | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| WO2009027650A1 (en) | 2007-08-24 | 2009-03-05 | The Institute Of Cancer: Royal Cancer Hospital | Materials and methods for exploiting synthetic lethality in brca-associated cancers |
| US20100267626A1 (en) | 2007-11-05 | 2010-10-21 | Novartis Ag | Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
| DE102008019838A1 (de) | 2008-04-19 | 2009-12-10 | Boehringer Ingelheim International Gmbh | Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
| US8431704B2 (en) | 2008-04-22 | 2013-04-30 | Janssen Pharmaceutica Nv | Quinoline or isoquinoline substituted P2X7 antagonists |
| EP2362775B1 (en) | 2008-11-20 | 2015-08-05 | GlaxoSmithKline LLC | Chemical compounds |
| KR20110122874A (ko) | 2009-03-06 | 2011-11-11 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 항바이러스 화합물 |
| EP2408454B1 (en) | 2009-03-18 | 2024-07-24 | Resverlogix Corp. | Novel anti-inflammatory agents |
| CN102458405B (zh) | 2009-04-22 | 2017-06-23 | 雷斯韦洛吉克斯公司 | 新抗炎剂 |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| US8841289B2 (en) | 2009-10-13 | 2014-09-23 | Merck Sharp & Dohme B.V. | Heterocyclic derivatives |
| WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| JP2013528635A (ja) | 2010-06-17 | 2013-07-11 | ノバルティス アーゲー | ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体 |
| JP2014520860A (ja) | 2011-07-13 | 2014-08-25 | ノバルティス アーゲー | タンキラーゼ阻害剤として使用するための４−オキソ−３，５，７，８−テトラヒドロ−４Ｈ−ピラノ｛４，３−ｄ｝ピルミニジニル化合物 |
| WO2013012723A1 (en) | 2011-07-13 | 2013-01-24 | Novartis Ag | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| US9163003B2 (en) | 2011-07-13 | 2015-10-20 | Novartis Ag | 4-piperidinyl compounds for use as tankyrase inhibitors |
| WO2013076090A1 (en) | 2011-11-25 | 2013-05-30 | Nerviano Medical Sciences S.R.L. | 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors |
| NO2797921T3 (cg-RX-API-DMAC7.html) | 2011-12-31 | 2018-02-03 | ||
| US9328111B2 (en) | 2011-12-31 | 2016-05-03 | Beigene Ltd. | Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as PARP inhibitors |
| CN104080773B (zh) | 2012-01-28 | 2016-12-28 | 默克专利股份公司 | 氮杂环化合物 |
| WO2013116182A1 (en) | 2012-01-31 | 2013-08-08 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as inhibitors of leukotriene production |
| DK2812323T3 (en) | 2012-02-09 | 2016-05-09 | Merck Patent Gmbh | TETRAHYDRO-quinazolinone derivatives BY TANKERS AND PARPINHIBITORER |
| US9340549B2 (en) | 2012-03-05 | 2016-05-17 | Amgen Inc. | Oxazolidinone compounds and derivatives thereof |
| MX346147B (es) * | 2012-03-07 | 2017-03-09 | Inst Of Cancer Research: Royal Cancer Hospital (The) | Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico. |
| ES2585044T3 (es) | 2012-03-28 | 2016-10-03 | Merck Patent Gmbh | Derivados de pirazinona bicíclicos |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| HUE028325T2 (en) | 2012-05-04 | 2016-12-28 | Merck Patent Gmbh | Pyrrolotriazines derivatives |
| WO2013177349A2 (en) | 2012-05-25 | 2013-11-28 | Glaxosmithkline Llc | Quinazolinediones as tankyrase inhibitors |
| CN104540830A (zh) | 2012-06-07 | 2015-04-22 | 霍夫曼-拉罗奇有限公司 | 端锚聚合酶的吡唑并嘧啶酮和吡唑并吡啶酮抑制剂 |
| EP2858995A1 (en) | 2012-06-07 | 2015-04-15 | F. Hoffmann-La Roche AG | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase |
| WO2013189904A1 (en) | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | Pyranopyridone inhibitors of tankyrase |
| KR20150011838A (ko) | 2012-06-20 | 2015-02-02 | 에프. 호프만-라 로슈 아게 | 탄키라아제 억제제로서의 피롤로피라존 |
| RU2654216C2 (ru) | 2012-08-08 | 2018-05-17 | Мерк Патент Гмбх | Производные (аза-)изохинолинона |
| EP2890696A1 (en) | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
| AR092211A1 (es) | 2012-09-24 | 2015-04-08 | Merck Patent Ges Mit Beschränkter Haftung | Derivados de hidropirrolopirrol |
| BR112015006524A8 (pt) | 2012-09-26 | 2019-08-20 | Merck Patent Gmbh | derivados de quinazolinona como inibidores de parp, seu processo de preparação, seu uso, medicamentos e conjunto (kit) |
| WO2014087165A1 (en) | 2012-12-06 | 2014-06-12 | University Of Bath | Tankyrase inhibitors |
-
2014
- 2014-09-11 US US14/917,788 patent/US9611223B2/en not_active Expired - Fee Related
- 2014-09-11 NO NO14766786A patent/NO3044221T3/no unknown
- 2014-09-11 CA CA2922469A patent/CA2922469A1/en not_active Abandoned
- 2014-09-11 AU AU2014320149A patent/AU2014320149A1/en not_active Abandoned
- 2014-09-11 ES ES14766786.9T patent/ES2666729T3/es active Active
- 2014-09-11 CN CN201480061828.6A patent/CN105722835B/zh not_active Expired - Fee Related
- 2014-09-11 EP EP14766786.9A patent/EP3044221B1/en active Active
- 2014-09-11 DK DK14766786.9T patent/DK3044221T3/en active
- 2014-09-11 WO PCT/GB2014/052752 patent/WO2015036759A1/en not_active Ceased
- 2014-09-11 JP JP2016542369A patent/JP6456392B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016531153A5 (cg-RX-API-DMAC7.html) | ||
| JP2015512885A5 (cg-RX-API-DMAC7.html) | ||
| JP7535500B2 (ja) | Ｔｅａｄモジュレーターとして有用なカルボキサミドおよびスルホンアミド誘導体 | |
| DE60215000T2 (de) | Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten | |
| DE60005850T2 (de) | Imidazo[1,2-a]pyridin- und pyrazolo[2,3-a]pyridinderivate | |
| JP6388915B2 (ja) | 置換５−（３，５−ジメチルイソオキサゾール−４−イル）インドリン−２−オン | |
| EP2917214B1 (en) | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors | |
| RU2014138194A (ru) | 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение | |
| CN104755473B (zh) | 2，3‑苯并二氮杂* | |
| TWI537259B (zh) | 吡啶酮衍生物 | |
| JP4926943B2 (ja) | Ｉｌ−１２産生を阻害する二塩 | |
| WO2007079982A1 (de) | (2 , 4 , 9-triaza-1 (2 , 4 ) -pyrimidina-3 ( 1 , 3 ) -benzenacyclononaphan-3 4-yl) -sulfoximin derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs | |
| UA108486C2 (xx) | Триазолопіридини | |
| SE461913B (sv) | Nya beta-laktamasinhibitor-foereningar vilka aer mellanprodukter vid frammstaellning av antibiotiskt verksamma beta-laktamasfoereningar | |
| CZ302359B6 (cs) | Triazolové slouceniny a jejich použití | |
| RS66420B1 (sr) | Heterociklično jedinjenje | |
| UA122228C2 (uk) | Похідні гідроксіестерів, спосіб їх отримання та фармацевтичні композиції, що їх містять | |
| HUP0303868A2 (hu) | Helyettesített triazol-diamin-származékok mint kináz inhibitorok és alkalmazások gyógyszerkészítmények előállítására | |
| DE102006041382A1 (de) | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren | |
| JP2020518672A (ja) | キナーゼ阻害活性を有する化合物、その製造方法及び用途 | |
| JP6001049B2 (ja) | Ｍｐｓ−１キナーゼ阻害剤としての置換ベンズイミダゾール類 | |
| JP2016519674A (ja) | 過剰増殖障害を治療または予防するための３−アセチルアミノ−１−（フェニル−ヘテロアリール−アミノカルボニルまたはフェニル−ヘテロアリール−カルボニルアミノ）ベンゼン誘導体 | |
| JP2013503190A (ja) | Ｒａｆ阻害化合物およびその使用方法 | |
| DE69321471T2 (de) | Dioxcyclobutenderivate als angiotensin ii antagonisten | |
| CN106458983A (zh) | 新型化合物 |